Acute strokes, also known as cerebrovascular accidents, are broadly classified as either ischemic or hemorrhagic. Acute strokes result in loss of blood flow, nutrients, and oxygen to a region of the brain, resulting in neuronal damage and subsequent neurological deficits. With early, focused treatment, rehabilitation programs, and long-term lifestyle changes, chances of a meaningful recovery can be maximized.
“Acute Ischemic Stroke Pipeline Insight, 2022” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Ischemic Stroke Market.
The Acute Ischemic Stroke Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
DelveInsight’s Acute Ischemic Stroke Report covers around 35+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Emerging Acute Ischemic Stroke Drugs Under Different Phases of Clinical Development Include:
• Nelonemdaz: GNT Pharma
• Tenecteplase: Genentech
• SP-8203: Shin Poong Pharmaceutical
• NONO-SC: NoNO Inc.
And Many Others
Further Acute Ischemic Stroke product details are provided in the report. Download the report to learn more about the emerging Acute Ischemic Stroke therapies at: https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-pipeline-insight
Acute Ischemic Stroke Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights about companies that are developing therapies for the treatment of Acute Ischemic Stroke with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Acute Ischemic Stroke Treatment.
-
Acute Ischemic Stroke key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Acute Ischemic Stroke Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Acute Ischemic Stroke market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Request for Sample PDF Report for Acute Ischemic Stroke Pipeline Assessment – https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-pipeline-insight
Some of the key companies in the Acute Ischemic Stroke Therapeutics Market include:
GNT Pharma, Genentech, Shin Poong Pharmaceutical, NoNO Inc., Genentech, Supergene, Tasly Pharmaceuticals, Pharmazz, GNT Pharma, NoNO, Angde Biotech Pharmaceuticals, NuvOx Pharma, Healios, Acticor Biotech, Biogen, ZZ Biotech, Revalesio Corporation, Abbvie, Pharming Group, Bristol-Myers Squibb, Roche, TrueBinding, Shin Poong Pharmaceuticals, NC Medical Research, JCR Pharmaceuticals.
Request for Sample PDF for Acute Ischemic Stroke Pipeline Report – https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Acute Ischemic Stroke Current Treatment Patterns
4. Acute Ischemic Stroke – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Acute Ischemic Stroke Late Stage Products (Phase-III)
7. Acute Ischemic Stroke Mid-Stage Products (Phase-II)
8. Acute Ischemic Stroke Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Acute Ischemic Stroke Discontinued Products
13. Acute Ischemic Stroke Product Profiles
14. Key Companies in the Acute Ischemic Stroke Market
15. Key Products in the Acute Ischemic Stroke Therapeutics Segment
16. Dormant and Discontinued Products
17. Acute Ischemic Stroke Unmet Needs
18. Acute Ischemic Stroke Future Perspectives
19. Acute Ischemic Stroke Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Trending Reports:
Age Related Vision Dysfunction Market
DelveInsight’s “Age Related Vision Dysfunction – Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Age Related Vision Dysfunction, historical and forecasted epidemiology as well as the Age Related Vision Dysfunction market trends in the United States, EU5 (Germany, Spain, Italy,France, and United Kingdom) and Japan.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-pipeline-insight
